Skip to main content
Clinical Trials/NCT00969891
NCT00969891
Completed
Not Applicable

Population Based Pharmacokinetic and Pharmacodynamic Dosage Model for Cytarabine, Daunorubicin and Etoposide for Acute Myeloid Leukemia

Mikkel Krogh-Madsen2 sites in 1 country23 target enrollmentSeptember 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Myeloid Leukemia
Sponsor
Mikkel Krogh-Madsen
Enrollment
23
Locations
2
Primary Endpoint
significant covariates from the PK study
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

The present study is not hypothesis driven but will explore the ability of pharmacokinetic-pharmacodynamic modelling to predict optimal dosage of the chemotherapeutic drugs used in therapy in adult patients with acute myeloid leukemia.

Registry
clinicaltrials.gov
Start Date
September 2009
End Date
August 2011
Last Updated
14 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Mikkel Krogh-Madsen
Responsible Party
Sponsor Investigator
Principal Investigator

Mikkel Krogh-Madsen

PhD student

University of Copenhagen

Eligibility Criteria

Inclusion Criteria

  • adult men and women with newly diagnosed acute myeloid leukemia

Exclusion Criteria

  • under age 18 years

Outcomes

Primary Outcomes

significant covariates from the PK study

Time Frame: after complete analysis of data

Secondary Outcomes

  • Amount of the three drugs in patient plasma samples(within 3 months of sampling)

Study Sites (2)

Loading locations...

Similar Trials